Correlation of p53 immunoreactivity and sequencing in patients with glioma

Molecular Carcinogenesis

Volumn 15, Issue 1, 1996, Pages 1-4

  Kyritsis, Athanassios P ^a   Xu, Ruishu ^a   Bondy, Melissa L ^a   Levin, Victor A ^a   Bruner, Janet M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Astrocytoma; Brain tumor; Glioblastoma; Immunohistochemistry

Indexed keywords

COMPLEMENTARY DNA; PROTEIN P53;

ARTICLE; ASTROCYTOMA; CONTROLLED STUDY; DNA SEQUENCE; GENE MUTATION; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

ADULT; BASE SEQUENCE; BRAIN NEOPLASMS; DNA PRIMERS; GENES, P53; GLIOBLASTOMA; GLIOMA; HUMANS; MOLECULAR SEQUENCE DATA; POINT MUTATION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030031072     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2744(199601)15:1<1::AID-MC1>3.0.CO;2-O     Document Type: Article

References (27)

1. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes Nature 362:847-849, 1993.
2. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas (see Comments). Nature 358:80-83, 1992.
3. Fults D, Pedone C Deletion mapping of the long arm of chromosome 10 in glioblastoma multiforme. Genes Chromosom Cancer 7:173-177, 1993.
4. Ohgaki H, Eibl RH, Schwab M, et al. Mutations of the p53 tumor suppressor gene in neoplasms of the human nervous system. Mol Carcinog 8:74-80, 1993
5. Sidransky D, Mikkelsen T, Schwechheimer K, Rosenblum ML, Cavanee W, Vogelstein B. Clonal expansion of p53 mutant cells is associated with brain tumor progression. Nature 355:846-847, 1992
6. Hayashi Y, Yamashita J, Yamaguchi K. Timing and role of p53 gene mutation in the recurrence of glioma Biochem Biophys Res Commun 180:1145-1150, 1991.
7. Oren M. The p53 cellular tumor antigen: Gene structure, expression and protein properties. Biochem Biophys Acta 823 67-78, 1985
8. Bruner JM, Connelly JH, Saya H p53 protein immunostaining in routinely processed paraffin-embedded sections. Mod Pathol 6:189-194, 1993.
9. Banks L, Matlashewski G, Crawford L. Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression. Eur J Biochem 739:529-534, 1986.
10. Nelson JS, Tsukuda Y, Schoenfeld D, Fulling K, LaMarche J, Peress N Necrosis as a prognostic criterion in malignant supratentorial astrocytic gliomas. Cancer 55:550-554, 1983.
11. Montine TJ, Bruner JM, Vandersteenhoven JJ, Dodge RK, Burger PC. Prognostic significance of p53 immunoreactivity in adult patients with supratentorial fibrillary astrocytic neoplasms. Diagn Mol Pathol 3:240-245, 1994.
12. Kyritsis AP, Bondy ML, Xiao M, et al. Germline p53 gene mutations m subsets of glioma patients. J Natl Cancer Inst 86:344-349, 1994.
13. Jaros E, Perry RH, Adam L, et al. Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumours. Br J Cancer 66:373-385, 1992.
14. Chozick BS, Pezzullo JC, Epstein MH, Finch PW. Prognostic im-plications of p53 overexpression in supratentorial astrocytic tumors Neurosurgery 35:831-837, 1994.
15. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers Science 253 49-53, 1991.
16. Frankel RH, Bayona W, Koslow M, Newcomb EW. p53 mutations in human malignant gliomas: Comparison of loss of heterozygosity with mutation frequency Cancer Res 52:1427-1433, 1992.
17. Newcomb E, Madonia W, Pishardy S, et al. A correlative study of p53 protein alteration and p53 gene mutation in glioblastoma multiforme Brain Pathol 3:229-235, 1993.
18. Rubio M-P, vonDeimling A, Chung R, et al Accumulation of wild type p53 protein in human astrocytomas Cancer Res 53:3465-3467, 1993.
19. Fan E, Levin DB, Glickman BW, Logan DM. Limitations in the use of SSCP analysis. Mutat Res 288:85-92, 1993
20. Wu JK, Ye Z, Darras BT Sensitivity of single-strand conformation polymorphism (SSCP) analysis in detecting p53 point mutations in tumors with mixed cell populations. Am J Hum Genet 52:1273-1275, 1993.
21. Louis DN, vonDeimling A, Chung R, et al. Comparative study of p53 gene and protein alterations in human astrocytic tumors. J Neuropathol Exp Neurol 52:31-38, 1993.
22. Runnebaum IB, Nagarajan M, Bowman M, Soto D, Sukumar S Mutations in p53 as potential molecular markers for human breast cancer. Proc Natl Acad Sci USA 88:10657-10661, 1991.
23. Koga H, Zhang SJ, Kumanishi T, et al. Analysis of p53 gene mutations in low- and high-grade astrocytomas by polymerase chain reaction-assisted single-strand conformation polymorphism and immunohistochemistry. Acta Neuropathol 87 225-232, 1994
24. Lang FF, Miller DC, Pisharody S, Koslow M, Newcomb EW. High frequency of p53 protein accumulation without p53 gene mutation in human juvenile pilocytic, low grade and anaplastic astrocytomas Oncogene 9:949-954, 1994.
25. Chozick BS, Weicker ME, Pezzullo JC, et al. Pattern of mutant p53 expression in human astrocytomas suggests the existence of alternate pathways of tumorigenesis. Cancer 73:406-415, 1994.
26. Rideout WMI, Coetze GA, Olumi AF, Jones PA. Methylcytosine as an endogenous mutagen in the human LDL receptor and p53 gene. Science 249:1288-1290, 1990
27. Zarbl H, Sukumar S, Arthur AV, Martin-Zanca D, Darbacid M. Direct mutagenesis of Ha-ras-1 oncogenes by N-nitroso-N-methylurea during initiation of mammary carcinogenesis in rats Nature 315:382-385, 1985